Professional
Added to YB: 2025-06-05
Pitch date: 2025-06-03
CATX [neutral]
Perspective Therapeutics, Inc.
-20.87%
current return
Author Info
Trickle Research is an independent microcap research firm. Visit the website.
Company Info
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Market Cap
$177.0M
Pitch Price
$3.21
Price Target
20.50 (+668%)
Dividend
N/A
EV/EBITDA
0.43
P/E
-1.98
EV/Sales
-21.01
Sector
Biotechnology
Category
growth
Perspective Therapeutics, Inc. - $CATX
CATX (update): Positive interim safety data from Ph1/2a [212Pb]VMT-α-NET therapy (no DLTs or serious adverse events) at higher dosing levels. 42 patients enrolled with potential correlation between weight & dose. Trading near cash despite promising data. Two other oncology programs advancing. $20.50 PT (12-24mo), 6 allocation.
Read full article (5 min)